Free Trial

Adlai Nortye (ANL) Competitors

Adlai Nortye logo
$1.58 +0.08 (+5.00%)
As of 07/2/2025 02:14 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ANL vs. SLRN, VOR, NBTX, BTMD, TVGN, CGC, PRQR, CRDF, EPRX, and TVRD

Should you be buying Adlai Nortye stock or one of its competitors? The main competitors of Adlai Nortye include Acelyrin (SLRN), Vor Biopharma (VOR), Nanobiotix (NBTX), biote (BTMD), Semper Paratus Acquisition (TVGN), Canopy Growth (CGC), ProQR Therapeutics (PRQR), Cardiff Oncology (CRDF), Eupraxia Pharmaceuticals (EPRX), and Tvardi Therapeutics (TVRD). These companies are all part of the "pharmaceutical products" industry.

Adlai Nortye vs. Its Competitors

Adlai Nortye (NASDAQ:ANL) and Acelyrin (NASDAQ:SLRN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.

In the previous week, Adlai Nortye had 1 more articles in the media than Acelyrin. MarketBeat recorded 1 mentions for Adlai Nortye and 0 mentions for Acelyrin. Adlai Nortye's average media sentiment score of 0.93 beat Acelyrin's score of 0.00 indicating that Adlai Nortye is being referred to more favorably in the media.

Company Overall Sentiment
Adlai Nortye Positive
Acelyrin Neutral

Adlai Nortye's return on equity of 0.00% beat Acelyrin's return on equity.

Company Net Margins Return on Equity Return on Assets
Adlai NortyeN/A N/A N/A
Acelyrin N/A -44.12%-39.02%

Adlai Nortye has higher revenue and earnings than Acelyrin.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adlai Nortye$5M11.62-$51.87MN/AN/A
AcelyrinN/AN/A-$381.64M-$2.69-0.84

Adlai Nortye currently has a consensus target price of $9.00, indicating a potential upside of 471.43%. Acelyrin has a consensus target price of $9.60, indicating a potential upside of 322.91%. Given Adlai Nortye's higher possible upside, equities analysts clearly believe Adlai Nortye is more favorable than Acelyrin.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Adlai Nortye
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Acelyrin
0 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.40

35.2% of Adlai Nortye shares are owned by institutional investors. Comparatively, 87.3% of Acelyrin shares are owned by institutional investors. 13.6% of Acelyrin shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Adlai Nortye has a beta of -0.95, meaning that its share price is 195% less volatile than the S&P 500. Comparatively, Acelyrin has a beta of 1.07, meaning that its share price is 7% more volatile than the S&P 500.

Summary

Adlai Nortye beats Acelyrin on 7 of the 12 factors compared between the two stocks.

Get Adlai Nortye News Delivered to You Automatically

Sign up to receive the latest news and ratings for ANL and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ANL vs. The Competition

MetricAdlai NortyeMED IndustryMedical SectorNASDAQ Exchange
Market Cap$55.35M$2.88B$5.54B$8.87B
Dividend YieldN/A2.64%5.39%4.10%
P/E RatioN/A21.3126.2319.90
Price / Sales11.62278.47413.23113.66
Price / CashN/A41.4736.1356.90
Price / Book2.287.518.045.38
Net Income-$51.87M-$55.05M$3.15B$248.50M
7 Day Performance1.61%2.07%1.44%2.04%
1 Month Performance-3.97%4.84%3.62%4.84%
1 Year Performance-56.73%5.37%34.68%20.23%

Adlai Nortye Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ANL
Adlai Nortye
1.9614 of 5 stars
$1.58
+5.0%
$9.00
+471.4%
-53.8%$55.35M$5M0.00127
SLRN
Acelyrin
N/A$2.27
flat
$9.60
+322.9%
N/A$229.17MN/A-0.92135
VOR
Vor Biopharma
N/A$1.83
+13.0%
N/AN/A$228.68MN/A-1.21140News Coverage
Analyst Upgrade
Gap Up
High Trading Volume
NBTX
Nanobiotix
2.4603 of 5 stars
$4.82
+1.9%
$8.00
+65.9%
-7.1%$227.21M$39.18M0.00100Gap Down
BTMD
biote
3.4091 of 5 stars
$4.13
+2.7%
$8.00
+93.7%
-45.2%$225.95M$197.19M6.77194
TVGN
Semper Paratus Acquisition
4.0218 of 5 stars
$1.22
-2.8%
$10.00
+723.0%
+75.8%$223.43MN/A0.003
CGC
Canopy Growth
2.6365 of 5 stars
$1.21
-1.2%
$2.00
+66.0%
-81.0%$221.56M$225.65M-0.303,150
PRQR
ProQR Therapeutics
2.1302 of 5 stars
$2.01
-1.3%
$8.00
+297.2%
+29.5%$212.00M$20.46M-5.76180News Coverage
CRDF
Cardiff Oncology
1.6866 of 5 stars
$3.19
+1.1%
$9.88
+210.0%
+72.6%$211.90M$680K-3.4620
EPRX
Eupraxia Pharmaceuticals
2.1729 of 5 stars
$5.89
+2.3%
$11.00
+86.8%
+117.1%$211.80MN/A-7.7529Analyst Revision
Gap Up
TVRD
Tvardi Therapeutics
N/A$22.61
-3.1%
$71.50
+216.2%
N/A$211.63M$7.14M0.0080

Related Companies and Tools


This page (NASDAQ:ANL) was last updated on 7/3/2025 by MarketBeat.com Staff
From Our Partners